Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

WVE vs MLTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MLTX Captures Overall Composite Edge (38.3 SELL vs 41.5 SELL), While WVE Leads 3–2 on Growth & Valuation Pillars

MLTX Overall Winner 6-Pillar Tally: WVE 3 – 2 MLTX (1 Tie) Matrix Metrics: WVE 4 – 4 MLTX

As of Nov 16, 2026, MoonLake Immunotherapeutics Class A (MLTX) captures the overall head-to-head institutional edge over Wave Life Sciences Ltd. (WVE) on higher Unified Composite conviction (38.3/100 SELL vs. 41.5/100 SELL) after splitting the core matrix 4–4 (led by Profitability & Quality, Options & Positioning), while WVE wins 3–2 across the 6-pillar growth and valuation breakdown. WVE trades at $2.89 (N/M Forward P/E, -320.9% operating margin) versus MLTX at $11.85 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While WVE currently prints a higher short-term Unified Composite Score (41.5/100 SELL vs. MLTX 38.3/100 SELL), MLTX captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -320.9% operating margin) and revenue trajectory (+0.0% vs. +73.0% YoY).
  • Defensive Composite Rating Caution: Although MLTX compares more favorably head-to-head, both WVE (41.5/100 SELL) and MLTX (38.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: WVE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.1); meanwhile MLTX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About WVE vs MLTX
WVE NASDAQ
Wave Life Sciences Ltd. Ordinary Shares
Pharmaceutical Preparations
$2.89
-7.82% 1D
Market Cap $621.3M
TTM Revenue $71M
Forward P/E N/M
Beta / 30D Vol 1.94β · 76% Vol
Unified Composite Score
41.5 / 100 SELL
Tech 21.0 Fund 46.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.2%), weak momentum, RSI 32
RSI-14: 32.1 · SMA20: $3.38 · SMA50: $3.69
MLTX NASDAQ Head-to-Head Winner
MoonLake Immunotherapeutics Class A Ordinary Shares
Pharmaceutical Preparations
$11.85
-5.2% 1D
Market Cap $1.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.61β · 90% Vol
Unified Composite Score
38.3 / 100 SELL
Tech 32.0 Fund 44.0 Flow 75.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -11.8%) with fading momentum, RSI 50
RSI-14: 49.5 · SMA20: $11.93 · SMA50: $11.82

6-Pillar Scorecard Institutional Category Breakdown (WVE 3 – 2 MLTX)

Columns: Metric · WVE · MLTX
1. Valuation Multiples WVE
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 6.6x N/M
2. Growth & Scale WVE
Revenue Growth (YoY) +73.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $71M N/A
Market Cap $621.3M $1.1B
3. Profitability & Quality MLTX
Gross Margin N/A N/A
Operating Margin -320.9% 0.0%
Net Profit Margin -296.9% 0.0%
Return on Equity (ROE) -78.8% -81.5%
4. Balance Sheet & Cash Flow WVE
Cash Generation (TTM) -$208M -$244M
Cash Flow Margin N/A N/A
Net Cash / Leverage $154M Net Cash $278M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MLTX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 605.7% (62nd %ile) 111.8% (7th %ile)
Put/Call OI Skew 0.31x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Distribution
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: WVE (4) vs MLTX (4)
Institutional Metric WVE MLTX Criterion Row Edge
Market Capitalization
Scale
$621.3M $1.1B Larger Scale MLTX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+73.0% +0.0% Higher Growth WVE
Operating Margin (TTM)
Profitability
-320.9% 0.0% Higher Margin MLTX
Net Profit Margin
Profitability
-296.9% 0.0% Higher Margin MLTX
Return on Equity (ROE)
Capital Efficiency
-78.8% -81.5% Higher ROE WVE
52-Week Range Position
Momentum
0% ($3–$21) 17% ($9–$23) Stronger Trend MLTX
Beta / 30D Volatility
Risk Regime
1.94β · 76% Vol 1.61β · 90% Vol Lower Realized Risk WVE
Unified Institutional Score
Composite Signal
41.5 / 100 (SELL) 38.3 / 100 (SELL) Higher Composite WVE
Trailing 12M Revenue (USD)
Operating Scale
$71M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$208M ($154M Net Cash) -$244M ($278M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MLTX +31.9 pp
WVE: -7.82% · MLTX: +24.08%
3M Horizon MLTX +17.98 pp
WVE: -45.46% · MLTX: -27.48%
6M Horizon MLTX +27.0 pp
WVE: -54.92% · MLTX: -27.92%
1Y Horizon MLTX +51.1 pp
WVE: -56.75% · MLTX: -5.65%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on WVE vs MLTX. Trailing 12-month operating profitability (WVE -320.9% vs MLTX 0.0%) and valuation multiples (WVE N/M vs MLTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

WVE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$71M
Gross MarginN/A
Op. Margin-320.9%
ROE / Fwd P/E-78.8% · N/M
MLTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-81.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
WVE BREAKDOWN
149d in phase · OBV NEUTRAL
Current IV 605.7%
IV Percentile 62nd %ile
Put/Call OI Skew 0.31x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact WVE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MLTX BREAKDOWN
103d in phase · OBV ACCUMULATION
Current IV 111.8%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact MLTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
WVE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $621.3M market capitalization and -320.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MLTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ WVE vs MLTX Key Questions & Quantitative Answers

As of Nov 16, 2026, MoonLake Immunotherapeutics Class A (MLTX) captures the overall head-to-head institutional edge over Wave Life Sciences Ltd. (WVE) on higher Unified Composite conviction (38.3/100 SELL vs. 41.5/100 SELL) after splitting the core matrix 4–4 (led by Profitability & Quality, Options & Positioning), while WVE wins 3–2 across the 6-pillar growth and valuation breakdown. WVE trades at $2.89 (N/M Forward P/E, -320.9% operating margin) versus MLTX at $11.85 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While WVE currently prints a higher short-term Unified Composite Score (41.5/100 SELL vs. MLTX 38.3/100 SELL), MLTX captures the overall institutional head-to-head verdict (4–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -320.9% operating margin) and revenue trajectory (+0.0% vs. +73.0% YoY). Defensive Composite Rating Caution: Although MLTX compares more favorably head-to-head, both WVE (41.5/100 SELL) and MLTX (38.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: WVE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.1); meanwhile MLTX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

WVE leads the Growth & Scale pillar: WVE posts +73.0% YoY revenue growth and +0.0% YoY earnings growth on $71M TTM revenue (N/A gross margin, -320.9% operating margin), compared with MLTX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, WVE generates $71M in USD-normalized revenue versus N/A for MLTX. In operating R&D and SG&A reinvestment, WVE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MLTX.

WVE screens cheaper on headline valuation multiples. WVE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin), whereas MLTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against WVE (-78.8% ROE) versus MLTX (-81.5% ROE) capital efficiency.

In options market volatility and institutional positioning, WVE carries 605.7% implied volatility (62nd %ile, Elevated (60th–80th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.94β · 76% Vol realized risk). By comparison, MLTX carries 111.8% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.61β · 90% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.